TABLE 4.
Cox proportional hazards model for 28‐day clinical improvement among severe or critical COVID‐19 following Tocilizumab versus standard‐of‐care treatments
| Unadjusted HR (95% CI) | p‐value | |
|---|---|---|
| Tocilizumab (vs. standard of care) | 6.739 (3.168–14.33) | <0.001* |
| Adjusted HR (95% CI) | p‐value | |
|---|---|---|
| Tocilizumab (vs. standard of care) | 4.936 (2.033–12.0) | <0.001* |
| Age (years) | 0.99 (0.956–1.032) | 0.726 |
| Charlson's comorbidity score | 0.65 (0.428–0.988) | 0.044* |
| Time to hospital admission (days) | 0.75 (0.613–0.927) | 0.007* |
| Need for invasive ventilation (yes vs. no) | 0.38 (0.157–0.905) | 0.029* |
| Glucocorticoids therapy (yes vs. no) | 0.54 (0.200–1.476) | 0.232 |
| PaO2:FiO2 ratio | 1.02 (1.005– 1.031) | 0.009* |
| CRP (mg/L) | 1.00 (0.997–1.004) | 0.817 |
| D‐Dimer (ng/ml) | 1.00 (1.000–1.000) | 0.077 |
| AST (IU/L) | 0.99 (0.961–1.010) | 0.234 |
| Platelets (×103) | 0.99 (0.996–1.002) | 0.554 |
| Haemoglobin (g/L) | 0.99 (0.973–1.020) | 0.760 |
Abbreviations: AST, aspartate aminotransferase; CI, confidence interval; COVID‐19, coronavirus disease 2019; CRP, C‐reactive protein; HR, hazard ratio.
*Statistically significant HR (p < 0.05).
a
−2 Log likelihood = 275.7; Chi‐square (df = 13) = 67.1; p < 0.001.